Dual Role of TGF-beta in Cancer Promotion and Suppression

Transforming growth factor (TGF)-beta signaling can have either tumor-suppressing or tumor-promoting effects in a cell- and context-dependent manner. The canonical Smad pathway is responsible for most of the TGF-β biological responses leading to tumor suppression (growth arrest, apoptosis, and prevention of immortalization) and tumor promotion (EMT, migration, invasion, and metastasis). Understanding the mechanisms by which the tumor-suppressing or tumor-promoting effects of TGF-β signaling can be regulated may have therapeutic potential for inhibiting the progression of several different types of human cancer.

Cat. No.DescriptionHost
ARG80123Human TGF beta1 ELISA Kit96 wells
ARG80498Human TGF-beta1 ELISA Kit96 wells
ARG80211Mouse TGF beta1 ELISA Kit96 wells
ARG80245Rat TGF beta1 ELISA Kit96 wells
ARG53688anti-TGF beta (pan) antibody500 ul
ARG10003anti-TGF beta antibody [2C5]100 ug
ARG10004anti-TGF beta antibody [2E6]100 ug
ARG10002anti-TGF beta antibody [TB21]100 ug
ARG65143anti-TGFBI antibody100 ug


1. Peter M. Siegel and Joan Massagué (2003) Nat Rev Cancer. 11, 807-21.
2. Hiroaki Ikushima and Kohei Miyazono (2010) Nat Rev Cancer. 10, 415-24
3. Jean-Jacques Lebrun (2012) ISRN Molecular Biology Volume 2012, Article ID 381428, 28 pages.
4. Rosemary J. Akhurst and Rik Derynck (2001) Trends Cell Biol. 11(11), S44-51
5. Lalage M Wakefield and Anita B Roberts (2002) Curr Opin Genet Dev. 12(1), 22-9.
6. Rik Derynck et al. (2001) Nat Genet. 29(2), 117-29.

Related to:
Brands: Arigo Biolaboratories
Product groups: Assays, Antibodies